Sanofi India Ltd.

SANOFI

₹6058.0

0.12% (7.0)

Market Cap

₹13,949 Cr.

P/E

33.75

Key Ratios

Edit Ratio's

Market cap

13,949 Cr

33.75

Prom Holding

60.40 %

ROE (%)

48.02

ROCE (%)

22.75

Div Yield (%)

1.93

Sales

2,038 Cr

OPM (%)

25.79 %

Debt to Equity

Edit Ratio's

About

Sanofi India Limited is a pharmaceutical company with a manufacturing facility in Goa and mult… Read more

Low

4902

52W Range

High

7600

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024

In Rs. Cr.	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Balance sheet
Net Block	—	—	—	—	—	—	—	—	315	313
Shareholders Funds	—	—	—	—	—	—	—	—	1,015	861
Profit & Loss
Operating Profit	—	—	—	—	—	—	—	—	487	490
Net Sales	—	—	—	—	—	—	—	—	1,996	2,013
Cash flow
Cash from Operating Activity	—	—	—	—	—	—	—	—	230	462
Net Capex (est)	—	—	—	—	—	—	—	—	10.00	35.80
Ratios
ROCE (%)	—	—	—	—	—	—	—	—	23.63	22.75
ROE (%)	—	—	—	—	—	—	—	—	59.39	48.02

Forensics

10 Yes

Positive for this company

1 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
ROE

Roe has decreased vs 10 year trend
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile

Market Share

6.24 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.32 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.05 %

(as of Mar 19)

Historic

Antineo Plastic - Market Share

1.97 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

0.55 %

(as of Mar 19)

Historic

Dermatology - Market Share

1.80 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

2.67 %

(as of Mar 19)

Historic

Neurological - Market Share

2.87 %

(as of Mar 19)

Historic

Pain - Market Share

1.60 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

3.38 %

(as of Mar 19)

Historic

Respiratory - Market Share

0.10 %

(as of Mar 19)

Historic

Sex Stimulants - Market Share

20.16 %

(as of Jul 22)

Historic

Vaccines - Market Share

0.12 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up

Operational Metrics

Domestic Sales Growth - YoY (%)

Sanofi India Ltd.

Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Sanofi India	6,058	33.75	13,949	60.4	-26.83	22.75	48.02
Caplin Point Lab	2,089	29.53	15,838	70.56	10.86	24	19.74
Natco Pharma	878.2	8.29	15,629	49.56	14.29	28.62	23.72
Marksans Pharma	250.15	29.82	11,347	43.87	26.51	18.97	15.19
Jubilant Pharmova	1,123.3	21.23	17,820	50.68	9.68	6.23	1.42
Procter&Gamble Healt	5,951	39.04	9,805	51.82	23.17	21.34	37.34
Alembic Pharma	958.8	32.69	19,072	69.67	16.66	14.87	11.24
Strides Pharma Scien	853.8	2.22	7,977	28.3	14.08	20.88	-3.32

Brands

Allegra

Avil

Combiflam

Corporate Actions

Consolidated Dividend

DATE

DETAILS

2025, Apr 25

Dividend Dividend of Rs.117 per share

2024, May 03

Dividend Dividend of Rs.117 per share

2024, Mar 07

Dividend Dividend of Rs.50 per share

2023, Apr 28

Dividend Dividend of Rs.194 per share

2023, Apr 28

Dividend Dividend of Rs.183 per share

Suppliers

Aarti Industries Ltd.
Shaily Engineering Plastics Ltd.
Aarti Drugs Ltd.
HLE Glascoat Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
Vidhi Specialty Food Ingredients Ltd.
NIIT Ltd.
Bliss GVS Pharma Ltd.
Wintac Ltd.
Take Solutions Ltd.

Showing 5 of 10

FAQs on Sanofi India Ltd. Business

What does Sanofi India do?

Sanofi India Limited sells a wide range of medications and dietary supplements for the treatment of various diseases in India. The company primarily operates through independent distributors.

Who are the competitors of Sanofi India?

Sanofi India major competitors are Caplin Point Lab, Natco Pharma, Marksans Pharma, Jubilant Pharmova, Procter&Gamble Healt, Alembic Pharma, Strides Pharma Scien.
Market Cap of Sanofi India is ₹13,949 Crs.
While the median market cap of its peers are ₹15,629 Crs.

Is Sanofi India financially stable compared to its competitors?

Sanofi India seems to be less financially stable compared to its competitors.
Altman Z score of Sanofi India is 3.26 and is ranked 7 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release		Jun Sep
Investor Presentation		Mar	Mar Sep Dec	Dec		Dec
Conference Call		Mar	Mar Sep Dec	Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Sanofi India Ltd.

View the discussion on ValuePickr

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Sanofi India Ltd.

Sanofi India Ltd.

Key Ratios

About

Timeline

Company Timeline

10 Yes

1 Neutral

6 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Other Income

Pledge

Revenue Recognition

Promoter Holding

Depreciation Effect

Retail Holding

Price & Performance

Capex vs ROCE

Share price

Working Capital

Debt

ROCE Strength

Balance Sheet Strength

ROE

Current vs Historic Valuation

Sales Growth

Margin Stability

Product Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Wise Break-Up - Domestic

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Domestic Sales Growth - YoY (%)

What does Sanofi India do?

Who are the competitors of Sanofi India?

Is Sanofi India financially stable compared to its competitors?

Sanofi India Ltd.

Sanofi India Ltd.

Key Ratios

About

Timeline

Company Timeline

10 Yes

1 Neutral

6 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Other Income

Pledge

Revenue Recognition

Promoter Holding

Depreciation Effect

Retail Holding

Price & Performance

Capex vs ROCE

Share price

Working Capital

Debt

ROCE Strength

Balance Sheet Strength

ROE

Current vs Historic Valuation

Sales Growth

Margin Stability

Product Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Wise Break-Up - Domestic

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Domestic Sales Growth - YoY (%)

Domestic Sales Growth - YoY (%)

What does Sanofi India do?

Who are the competitors of Sanofi India?

Is Sanofi India financially stable compared to its competitors?

SIGN UP FOR FREE